



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

ACTUAL FIGURES

Nov 25	Clinical Audit Yellow highlighted reports are part of HRDM work	BRAN	COM	DHG	HAV	HOW	OAK	DERB
Antibiotics (AB)	AB-01 Antibiotics on repeat	80	134	125	72	84	124	193
	AB-01a Antibiotics on repeat excl Hipprex, & Lymecycline	43	90	79	47	46	87	139
	AB-02 Broad spectrum antibiotics issued in last 1m excl Quinolones	11	27	22	13	28	13	87
	AB-03 Quinolones issued in last 1m	4	9	2	4	4	4	12
Anti-Coagulants (AC)	AC-01 Warfarin, prescribed antibiotics in past 7-37 days with no coding of INR result 3-7 days after initiation	2	3	0	0	1	0	3
	AC-02 NSAIDS and Warfarin or DOACs	0	0	1	0	0	2	0
	AC-03 Antiplatelet and Warfarin or DOACs	11	21	26	31	48	13	30
	AC-05 DOACs with no Us & Es + FBC + LFT in last 12m (15/12)	4	3	3	3	4	2	7
	AC-09 On DOAC - Check CrCl as not done in last 1y	0	2	2	1	0	0	0
	AC-12 On DOAC - Check U+E as none in last 3m + CrCl <30	3	5	5	3	11	2	1
	AC-13 On DOAC - Check U+E as none in last 6m + CrCl 30-59	14	32	17	20	40	2	6
	AC-15 On DOAC - Review as last Hb <9g/dl in last 1y	5	1	4	2	4	1	3
Cardiology (CARD)	CARD-02 ?Stop diltiazem or verapamil as has CHF	0	1	2	4	2	1	5
	CARD-03 On higher dose amitriptylline preparation with diagnosis of heart problem (arrhythmia, cardiomyopathy) or orthostatic hypotension with Parkinsons	0	6	4	2	3	3	2
	CARD-05 ?Review PDE5 inhibitor issued past 3 months or on repeat and on nicorandil or nitrates	0	5	3	1	5	6	0
	CARD-08 Statin first issue in past 3 months, without LFTs past 0-6 months	3	4	5	4	14	0	8
	CARD-09 Simvastatin >20mg with amlod, dilt, verapamil, amiodarone	0	0	0	3	0	1	0
	CARD-10 omeprazole/esomeprazole with clopidogrel	0	4	2	4	1	5	1
	CARD-12 Mirabegron with no BP monitoring past 9m	6	6	7	6	5	2	11
	CARD-13 Amiodarone without LFTs, U+Es or TSH within 6 months	2	1	3	0	2	1	3
	CARD-15 On febuxostat - Review as has CVD	0	1	2	0	0	0	1
Endo- crinology (END)	END-3 Review Metformin as no UE in last 15m	9	17	9	9	15	1	30
	END-3a Review Metformin as NO B12 test ever	7	50	33	24	20	16	212
	END-4 Review Carbimazole as no TSH in last 1year	0	1	3	1	0	1	1
	END-6 Hypothyroidism - Check TSH as none in last 15m (should be every 12m)	38	32	29	12	17	6	7
	END-7 DM - last HBA1c >=48 + 2 readings (exc. GDM & steroid-DM in last 1y or HbRx), excl pre-diabetes or DIAB resolved	1	1	4	0	3	0	2
	END-8 Diabetic + GLP-1 medication	60	115	115	187	108	46	229
	END-9 Non Diabetic + GLP-1 medication	83	157	164	247	13	119	314



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT
ACTUAL FIGURES

Nov 25	Clinical Audit Yellow highlighted reports are part of HRDM work	BRAN	COM	DHG	HAV	HOW	OAK	DERB
Gastro- enterology (GAS)	GAS-01 ?Start PPI or H2RA history of PUD or GI bleed + antiplatelet, anticoagulant, SSRI, NSAID or nicorandil	1	11	5	7	8	2	11
	GAS-02 > 1 issue of aspirin or NSAIDs in patient > 65yr in past 3m and no gastroprotection last 3m	0	1	1	0	1	0	1
	GAS-03 45yrs + NSAID on repeat + no PPI or H2	0	3	3	1	4	2	2
	GAS-04 ?Start PPI or H2RA as on "antiplatelet + anticoagulant" OR "aspirin + antiplatelet"	0	0	1	2	5	1	0
	GAS-05 Metoclopramide - on repeat	2	9	4	3	6	6	14
	GAS-06 Domperidone - on repeat	0	4	1	1	1	3	2
	GAS-08 Mesalazine patients without U+E in past 12 months	3	16	12	11	4	0	16
	GAS-09 PPI - Maintenance Dose on repeat	190	267	324	201	213	176	433
	GAS-10 PPI - High Dose on repeat	648	1251	1149	1095	1273	719	1958
Mental Health (MH)	MH-1 Antidepressant on repeat (>3m, excl amitriptylline and duloxetine), no medication review in past 1 year	90	100	55	41	23	91	68
	MH-2 All patients with dementia, but not psychosis with an Antipsychotic on repeat (issued past 6 weeks)	4	12	3	10	4	5	7
	MH-5 Lithium prescribed, not had U+Es, TSH and calcium in 6m, or Li level in past 3m	2	1	3	0	4	2	6
	MH-6 On citalopram 40mg or escitalopram 20mg tablets - Reduce dose as age >65y	0	3	0	0	3	3	2
Miscell- aneous (MISC)	MISC-4 ?Osteoporosis review - Prednisolone (glucocorticoid) on repeat, not on calcium or bisphosphonate, >18y	15	25	31	15	21	18	36
	Misc-4a ?Osteoporosis review - Prednisolone on repeat, not on repeat PPI or H2RA	2	12	9	2	7	4	9
	MISC-5 Quinine on repeat	1	3	4	1	5	8	6
Medication Reviews (MR)	MR-1 Polypharmacy 10 or more medications on repeat without medication review past 18m	34	21	2	15	1	1	15
	MR-2 Repeat medication + no review done in last 1y	956	1477	1102	942	987	894	2336
	MR-3 Repeat medication + no review done in last 2y	172	596	363	265	611	358	1204
	MR-4 Repeat medication + no review done in last 3y	61	436	176	44	392	243	815
	MR-5 Repeat medication + no review done in last 5+y	32	178	88	0	59	54	352



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

ACTUAL FIGURES

Nov 25	Clinical Audit Yellow highlighted reports are part of HRDM work	BRAN	COM	DHG	HAV	HOW	OAK	DERB
Prescription Drug Depend- ency (PDD)	PDD-1 High dose opioids on repeat excl cancer or EoL patients*	3	4	6	0	7	3	9
	PDD-2 Gabapentinoids on repeat	292	311	176	175	222	99	427
	PDD-3 Benzodiazepines on repeat	4	70	47	26	54	27	76
	PDD-4 Z drugs on repeat	5	50	42	14	38	27	45
	PDD-5 Patient in any of 1-4 searches	300	400	249	204	295	147	519
	PDD-5b Patient in 2 search drug results	4	31	20	10	24	9	36
	PDD-5c Patient in 3 search drug results	0	4	2	1	2	0	2
	PDD-5d Patient in 4 search drug results	0	0	0	0	0	0	0
Renal (REN)	REN-01 NSAID on repeat with latest eGFR <45	0	1	2	0	0	0	0
	REN-02 ?Review Allopurinol 300mg as latest eGFR <30	1	2	0	2	1	1	1
	REN-03 Review ACE or ARB or Diuretic as no UE done in last 12 months (15/12)	59	91	26	23	43	15	79
	REN-04 On spironolactone or eplerenone without creatinine and K+ in past 6m	5	10	17	9	12	6	13
	REN-05 Ciclosporin issued (in past 3 months), no FBC/U+Es/LFTs HbA1C 14/52 or BP 52/52	0	0	0	0	1	1	0
	REN-06 CKD 4-5 or CKD + latest eGFR <30 - Check U+E as none in last 9m (should be 3-6m)	4	14	0	12	8	5	12
	REN-07 Possible CKD 3-5 as latest 2 eGFRs 3m apart <60 + no eGFR >=60 in 3m before latest	0	0	0	0	0	0	1
	REN-08 Non preferred NSAIDs ON REPEAT(excl Ibuprofen, Naproxen)	21	31	20	7	19	46	59
	REN-09 NSAID on repeat issued in last 1m to 60+ yrs	7	30	29	1	9	22	46
	REN-10 NSAID on repeat + issued in last 1m + last eGFR < 60	2	3	2	0	1	2	2
Respiratory (RESP)	RESP-1 ?Stop Betablocker as Asthma + not checked in last 1y	9	21	13	19	18	10	22
	RESP-2a ?Review Inhalers as SABA with no ICS in asthma 12+ yrs	0	3	0	0	0	0	0
	RESP-3 Asthma - Review as 2 or more oral prednisolone in last 12m (+ no COPD)	45	57	73	35	62	26	125
	RESP-4 Asthma - Review as 12 or more SABA inhalers in last 12m (+ no COPD)	1	26	8	9	5	7	11
	RESP-4a Asthma - Review as 5>= SABA inhalers in last 12m (+ no COPD)	17	134	39	72	46	42	110
	RESP-4b Asthma- Review as 3>= SABA inhalers in last 12m (+ no COPD)	34	232	143	163	132	85	299
	RESP-5 Asthma + no COPD on combined ICS + LABA	205	266	468	257	196	274	506



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

ACTUAL FIGURES

Nov 25	Clinical Audit Yellow highlighted reports are part of HRDM work	BRAN	COM	DHG	HAV	HOW	OAK	DERB
Rheumatology (RH)	RH-02 ?Start folic acid as methotrexate on repeat	0	0	0	0	2	0	1
	RH-04 Review Allopurinol or Febuxostat as no UE or Urate in 12/12 (15/12)	10	17	11	8	12	7	19
	RH-05 Azathioprine patients without FBC/LFTs/U+Es in prior 3 months	1	2	4	2	1	3	7
	RH-06 Leflunomide without FBC, LFTs in 3 months and BP in past 6 months	2	2	3	5	2	1	6
	RH-07 Mycophenolate issued without FBC, U+Es, LFTs , ESR & CRP in past 12 weeks	3	1	2	0	5	3	3
	RH-10 Sulfasalazine patient with no U+Es in prior 12 months	0	0	0	0	0	0	0
	RH-11 Methotrexate without FBC/U+Es/LFT/CRP/ESR s in past 14 weeks coded	4	7	17	10	13	7	19
Women's Health (WH)	WH-1 Review COCP as VTE or Thrombophilia (UK MEC 4)	0	1	0	0	0	0	0
	WH-2 Review oestrogen as history of breast cancer (no HRT review in last 1y)	0	0	0	0	1	1	3
	WH-3 Review Oestrogen only HRT as has uterus and no LNG-IUS	0	7	4	3	6	3	4
	WH-4 Review COCP as >35y + Smoker (UK MEC 3/4)	0	0	0	0	0	2	1
	WH-5 Review COCP as BMI>35 (UK MEC 3)	1	0	1	1	2	0	2
Teratogenic Drugs	END-5 Carbimazole child bearing age NOT given LARCs advice	0	0	0	0	0	1	0
	MISC-6 Males 16-55 on Sodium Valproate with no advice about side effects of drug treatment coded	0	0	0	0	0	0	0
	WH-6 On teratogenic drugs, childbearing age, no LARCs advice in last 18m	1	1	0	1	2	1	1
	WH-7 Valproate with no completed risk acknowledgement form on record in last 13m	1	6	0	1	1	0	4
	WH-7a Valproate with no referral for risk acknowledgement form on record in last 13m	0	0	0	0	0	0	0
	WH-8 Topiramate on repeat and no Advice or LARCs code on record	0	0	0	0	0	0	0
	WH-8a Topiramate on repeat and no Pregnancy Prevention Program code on record	0	1	1	0	0	0	5



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

DENOMINATOR SEARCHES - % of total denominator Out of Scope

Nov 25	Clinical Audit	BRAN	COMB	DHG	HAV	HOW	OAK	DERB
Antibiotics (AB)	AB-01 Antibiotics on repeat (as % of total registered patients)	2%	1%	1%	1%	1%	1%	1%
	AB-01a Antibiotics on repeat excl Hipprex, & Lymecycline	1%	1%	1%	1%	1%	1%	1%
	AB-02 Broad spectrum antibiotics issued in last 1m (as % of all antibiotics issued in last 1m)	4%	8%	6%	5%	8%	4%	11%
	AB-03 Quinolones issued in last 1m (as % of all antibiotics issued in last 1m)	2%	3%	1%	1%	1%	1%	1%
Anti-Coagulants (AC)	AC-01 Warfarin , prescribed antibiotics in past 7-37 days with no coding of INR result 3-7 days after initiation	8%	8%	0%	0%	3%	0%	4%
	AC-02 NSAIDS and Warfarin or DOACs	0%	0%	0%	0%	0%	1%	0%
	AC-03 Antiplatelet and Warfarin or DOACs	5%	6%	7%	10%	11%	6%	6%
	AC-05 DOACs with no Us & Es + FBC + LFT in last 12m (15/12)	2%	1%	1%	1%	1%	1%	1%
	AC-09 On DOAC - Check CrCl as not done in last 1y	0%	1%	1%	0%	0%	0%	0%
	AC-10 On DOAC - Check FBC + LFT as none in last 15m (should be every 12m)	2%	1%	1%	1%	1%	1%	1%
	AC-11 On DOAC - Check U+E as none in last 1y + CrCl >=60	3%	3%	2%	2%	1%	0%	1%
	AC-12 On DOAC - Check U+E as none in last 3m + CrCl <30	1%	1%	1%	1%	2%	1%	0%
	AC-13 On DOAC - Check U+E as none in last 6m + CrCl 30-59	6%	9%	4%	6%	9%	1%	1%
	AC-15 On DOAC - Review as Hb <9g/dl in last 1y	2%	0%	1%	1%	1%	0%	1%
Cardiology (CARD)	CARD-02 ?Stop diltiazem or verapamil as has CHF	0%	2%	5%	11%	3%	8%	7%
	CARD-03 On higher dose amitriptyline preparation with diagnosis of heart problem (arrhythmia, cardiomyopathy) or orthostatic hypotension with Parkinsons	0%	6%	11%	2%	5%	9%	2%
	CARD-05 ?Review PDE5 inhibitor issued past 3 months or on repeat and on nicorandil or nitrates	0%	4%	2%	1%	4%	7%	0%
	CARD-06 Review ACE, ARB, Entresto or Aliskiren as 2 or more of these	0%	0%	0%	5%	0%	0%	2%
	CARD-08 Statin first issue in past 3 months, without LFTs past 0-6 months	0%	0%	0%	0%	1%	0%	0%
	CARD-09 Simvastatin >20mg with amlod, dilt, verapamil, amiodarone	0%	0%	0%	4%	0%	3%	0%
	CARD-10 omeprazole/esomeprazole with clopidogrel	0%	0%	0%	0%	0%	1%	0%
	CARD-12 Mirabegron with no BP monitoring past 9m	55%	60%	33%	33%	31%	29%	65%
	CARD-13 Amiodarone without LFTs, U+Es or TSH within 6 months	33%	11%	27%	0%	22%	17%	27%
	CARD-15 On febuxostat - Review as has CVD	0%	25%	50%	0%	0%	0%	11%



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

DENOMINATOR SEARCHES - % of total denominator Out of Scope

Nov 25	Clinical Audit	BRAN	COMB	DHG	HAV	HOW	OAK	DERB
Endo- crinology (END)	END-3 Review Metformin as no UE in last 15m	4%	4%	3%	2%	4%	0%	4%
	END-3a Review Metformin as NO B12 test ever	3%	13%	10%	5%	5%	8%	29%
	END-4 Review Carbimazole as no TSH in last 1year	0%	7%	21%	8%	0%	20%	5%
	END-6 Hypothyroidism - Check TSH as none in last 15m (should be every 12m)	13%	6%	5%	3%	3%	2%	1%
	END-7 DM - last HBA1c >=48 + 2 readings (exc. GDM & steroid-DM in last 1y or HbRx), excl pre-diabetes or DIAB resolved	0%	0%	1%	0%	0%	0%	0%
	END-8 Diabetic + GLP-1 medication	13%	17%	19%	26%	14%	10%	19%
	END-9 Non Diabetic + GLP-1 medication	2%	2%	2%	4%	0%	2%	2%
Gastro- enterology (GAS)	GAS-1 ?Start PPI or H2RA history of PUD or GI bleed + antiplatelet, anticoagulant, SSRI, NSAID or nicorandil	0%	1%	0%	0%	0%	0%	0%
	GAS-2 > 1 issue of aspirin or NSAIDs in patient > 65yr in past 3m and no gastroprotection last 3m	0%	3%	3%	0%	7%	0%	3%
	GAS-3 45yrs + NSAID on repeat + no PPI or H2	0%	2%	3%	5%	11%	4%	1%
	GAS-4 ?Start PPI or H2RA as on " antiplatelet + anticoagulant " OR " aspirin + antiplatelet "	0%	0%	2%	4%	6%	4%	0%
	GAS-09 PPI - Maintenance Dose on repeat	4%	3%	3%	2%	3%	2%	2%
	GAS-10 PPI - High Dose on repeat	13%	13%	11%	13%	15%	9%	10%
Mental Health (MH)	MH-1 Antidepressant on repeat (>3m, excl amitriptylline and duloxetine), no medication review in past 1 year	23%	11%	9%	5%	4%	25%	4%
	MH-2 All patients with dementia, but not psychosis with an Antipsychotic on repeat (issued past 6 weeks)	11%	13%	6%	8%	3%	8%	6%
	MH-5 Lithium prescribed, not had U+Es, TSH and calcium in 6m, or Li level in past 3m	40%	13%	43%	0%	50%	50%	32%
	MH-6 On citalopram 40mg or escitalopram 20mg tablets - Reduce dose as age >65y	0%	6%	0%	0%	8%	14%	2%
Miscell- aneous (MISC)	MISC-4 ?Osteoporosis review - Prednisolone (glucocorticoid) on repeat , not on calcium or bisphosphonate, >18y	38%	49%	48%	43%	39%	67%	48%
	Misc-4a ?Osteoporosis review - Prednisolone on repeat, not on repeat PPI or H2RA	5%	24%	14%	6%	13%	15%	12%
Medication Reviews (MR)	MR-1 Polypharmacy 10 or more medications on repeat without medication review past 18m	11%	4%	0%	3%	0%	0%	2%
	MR-2 Repeat medication + no review done in last 1y	36%	28%	19%	20%	19%	23%	24%
	MR-3 Repeat medication + no review done in last 2y	6%	11%	6%	6%	12%	9%	12%
	MR-4 Repeat medication + no review done in last 3y	2%	8%	3%	1%	7%	6%	8%
	MR-5 Repeat medication + no review done in last 5+y	1%	3%	1%	0%	1%	1%	4%



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT
DENOMINATOR SEARCHES - % of total denominator Out of Scope

Nov 25	Clinical Audit	BRAN	COMB	DHG	HAV	HOW	OAK	DERB
Renal (REN)	REN-1 NSAID on repeat with latest eGFR <45	0%	1%	2%	0%	0%	0%	0%
	REN-2 ?Review Allopurinol 300mg as latest eGFR <30	2%	2%	0%	2%	1%	1%	1%
	REN-03 Review ACE or ARB or Diuretic as no UE done in last 12 months (15/12)	8%	7%	2%	2%	3%	2%	4%
	REN-4 On spironolactone or eplerenone without creatinine and K+ in past 6m	17%	19%	18%	14%	13%	14%	10%
	REN-5 Ciclosporin issued (in past 3 months), no FBC/U+Es/LFTs HbA1C 14/52 or BP 52/52	0%	0%	0%	0%	0%	100%	0%
	REN-6 CKD 4-5 or CKD + latest eGFR <30 - Check U+E as none in last 9m (should be 3-6m)	17%	22%	0%	22%	12%	18%	15%
	REN-08 Non preferred NSAIDs ON REPEAT(excl Ibuprofen, Naproxen) as a % of all NSAIDs on repeat	47%	21%	16%	21%	38%	58%	29%
	REN-09 NSAID on repeat issued in last 1m to 60+ yrs as a % of patients 60+ years	0%	1%	1%	0%	0%	1%	1%
	REN-10 NSAID on repeat + issued in last 1m + last eGFR < 60 as a % of all NSAIDs on repeat issued in last 1m	3%	1%	1%	0%	1%	2%	1%
Respiratory (RESP)	RESP-1 ?Stop Betablocker as Asthma + not checked in last 1y	11%	12%	10%	13%	11%	10%	8%
	RESP-2a ?Review Inhalers as SABA with no ICS in asthma	0%	0%	0%	0%	0%	0%	0%
	RESP-3 Asthma - Review as 2 or more oral prednisolone in last 12m (+ no COPD)	7%	4%	5%	3%	6%	3%	6%
	RESP-4 Asthma - Review as 12 or more SABA inhalers in last 12m (+ no COPD)	0%	2%	1%	1%	0%	1%	1%
	RESP-4a Asthma - Review as 5>= SABA inhalers in last 12m (+ no COPD)	2%	10%	3%	6%	5%	4%	6%
	RESP-4b Asthma - Review as 3>= SABA inhalers in last 12m (+ no COPD)	5%	17%	10%	13%	13%	9%	15%
	RESP-5 Asthma + no COPD on combined ICS + LABA	30%	19%	33%	21%	20%	28%	26%
Rheuma- tology (RH)	RH-02 ?Start folic acid as methotrexate on repeat	0%	0%	0%	0%	5%	0%	2%
	RH-04 Review Allopurinol or Febuxostat as no UE or Urate in 12/12 (15/12)	15%	16%	8%	6%	9%	8%	10%
	RH-05 Azathioprine patients without FBC/LFTs/U+Es in prior 3 months	17%	17%	27%	18%	9%	23%	18%
	RH-06 Leflunomide without FBC, LFTs in 3 months and BP in past 6 months	50%	50%	75%	50%	33%	20%	46%
	RH-07 Mycophenolate issued without FBC, U+Es, LFTs , ESR & CRP in past 12 weeks	100%	33%	40%	0%	56%	60%	60%
	RH-10 Sulfasalazine patient with no U+Es in prior 12 months	0%	0%	0%	0%	0%	0%	0%
	RH-11 Methotrexate without FBC/U+Es/LFT/CRP/ESR s in past 14 weeks coded	44%	32%	46%	20%	33%	19%	35%



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT
DENOMINATOR SEARCHES - % of total **denominator** Out of Scope

Nov 25	Clinical Audit	BRAN	COMB	DHG	HAV	HOW	OAK	DERB
Women's Health (WH)	WH-1 Review COCP as VTE or Thrombophilia (UK MEC 4)	0%	1%	0%	0%	0%	0%	0%
	WH-2 Review oestrogen as history of breast cancer (no HRT review in last 1y)	0%	0%	0%	0%	0%	0%	1%
	WH-3 Review Oestrogen only HRT as has uterus and no LNG-IUS	0%	3%	1%	1%	2%	1%	1%
	WH-4 Review COCP as >35y + Smoker (UK MEC 3/4)	0%	0%	0%	0%	0%	2%	0%
	WH-5 Review COCP as BMI>35 (UK MEC 3)	17%	0%	1%	1%	2%	0%	1%
Teratogenic Drugs	END-5 Carbimazole child bearing age NOT given LARCs advice	0%	0%	0%	0%	0%	33%	0%
	MISC-6 Males 0-55 on Sodium Valproate with no advice about side effects of drug treatment coded	0%	0%	0%	0%	0%	0%	0%
	WH-6 On teratogenic drugs , childbearing age, no LARCs advice in last 18m	1%	0%	0%	1%	1%	1%	0%
	WH-7 Valproate with no completed risk acknowledgement form on record in last 13m	100%	75%	0%	50%	50%	0%	44%
	WH-7a Valproate with no referral for risk acknowledgement form on record in last 13m	0%	0%	0%	0%	0%	0%	0%
	WH-8 Topiramate on repeat and no Advice or LARCs code on record	0%	0%	0%	0%	0%	0%	0%
	WH-8a Topiramate on repeat and no Pregnancy Prevention Program code on record	0%	13%	13%	0%	0%	0%	29%

0-5% of denominator

5-10% of denominator

>10% of denominator



LONG TERM CONDITIONS DASHBOARD
FIGURES BY PROPORTION OF DENOMINATOR FOR EACH INDICATOR

Nov 25	BRAN	COMB	DHG	HAV	HOW	OAK	DERB	SPC Total
AC-05 DOACs with no Us & Es + FBC + LFT in last 12m (15/12)	1.8%	0.8%	0.8%	0.9%	0.9%	0.9%	1.3%	1.1%
END-3 Review Metformin as no UE in last 15m	3.9%	4.3%	2.8%	2.0%	3.7%	0.5%	4.1%	3.3%
END-6 Hypothyroidism - Check TSH as none in last 15m (should be every 12m)	12.6%	6.1%	5.3%	2.9%	3.2%	2.0%	0.9%	4.2%
END-7 DM - last HBA1c >=48 + 2 readings (exc. GDM & steroid-DM in last 1y or HbRx), excl pre-diabetes or DIAB resolved	0.2%	0.2%	0.7%	0.0%	0.4%	0.0%	0.2%	0.2%
REN-03 Review ACE or ARB or Diuretic as no UE done in last 12 months (15/12)	8.4%	6.7%	1.9%	1.7%	2.5%	1.7%	3.5%	3.5%
RESP-3 Asthma - Review as 2 or more oral prednisolone in last 12m (+ no COPD)	6.5%	4.1%	5.2%	2.9%	6.2%	2.7%	6.3%	4.9%
X 1 LTC Diabetes and no hbA1C in last 12m (15/12)	8.6%	6.8%	4.0%	2.9%	5.5%	3.4%	5.2%	5.1%
X 2 LTC Hypertension no BP in last 12m (15/12)	11.5%	4.4%	4.1%	2.6%	3.7%	2.2%	7.5%	5.0%
X 3 LTC CHD no BP in last 12m (15/12)	9.6%	7.8%	3.5%	1.8%	3.4%	1.4%	4.4%	4.4%
X 4 LTC CVD Stroke TIA no BP in last 12m (15/12)	4.5%	3.9%	2.2%	1.9%	3.0%	2.8%	6.3%	3.7%
x 5 LTC CHOL004 HAID % missing (Lower % is better -Achievement target is 50%)	38.6%	41.8%	29.4%	24.2%	37.5%	30.7%	39.0%	35.1%

0-5% of denominator

5-10% of denominator

>10% of denominator

Met QOF threshold for max points (HAID)



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

WORK TO DO

Work To Do this month (Red)	BRAN	COMB	DHG	HAV	HOW	OAK	DERB	Nov-25	Oct-25	Sep-25	Aug-25	SITES TO DO (GP / PHARMACIST / NURSE)	CENTRAL TO DO
CARD-05 ?Review PDE5 inhibitor issued past 3 months or on repeat and on nicorandil or nitrates	0	5	3	1	5	6	0	20	21			Site	
CARD-09 Simvastatin >20mg with amlod, dilt, verapamil, amiodarone	0	0	0	3	0	1	0	4	7			Site	
CARD-10 omeprazole/esomeprazole with clopidogrel	0	4	2	4	1	5	1	17	23			Site	
GAS-03 45yrs + NSAID on repeat + no PPI or H2	0	3	3	1	4	2	2	15	18			Site	
GAS-04 ?Start PPI or H2RA as on "antiplatelet + anticoagulant" OR "aspirin + antiplatelet"	0	0	1	2	5	1	0	9	10			Site	
MH-6 On citalopram 40mg or escitalopram 20mg tablets - Reduce dose as age >65y	0	3	0	0	3	3	2	11	15			Site	
WH-3 Review Oestrogen only HRT as has uterus and no LNG-IUS	0	7	4	3	6	3	4	27	37			Site	
WH-5 Review COCP as BMI>35 (UK MEC 3)	1	0	1	1	2	0	2	7	11			Site	
AB-02 Broad spectrum antibiotics issued in last 1m excl Quinolones	11	27	22	13	28	13	87	201	296	246	228	Make teams aware	



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

WORK TO DO

Work To Do this month (Red)	BRAN	COMB	DHG	HAV	HOW	OAK	DERB	Nov-25	Oct-25	Sep-25	Aug-25	SITES TO DO (GP / PHARMACIST / NURSE)	CENTRAL TO DO
MH-1 Antidepressant on repeat (>3m, excl amitriptylline and duloxetine), no medication review in past 1 year	90	100	55	41	23	91	68	468	596	551	531	Continue work on this	
AB-01a Antibiotics on repeat excl Hipprex, & Lymecycline	43	90	79	47	46	87	139	531	524	529	526	Copies of audit to PD please	
RESP-4 Asthma - Review as 12 or more SABA inhalers in last 12m (+ no COPD)	1	26	8	9	5	7	11	67	68	68	73	Pharmacists to set default review to 3m (84 days)	Alerts to patients
RESP-4a Asthma - Review as 5>= SABA inhalers in last 12m (+ no COPD)	17	134	39	72	46	42	110	460	472	488	497	Pharmacists to set default review to 3m (84 days)	Alerts to patients
RESP-5 Asthma + no COPD on combined ICS + LABA	205	266	468	257	196	274	506	2172	2096	2102	2075		
END-8 Diabetic + GLP-1 medication	60	115	115	187	108	46	229	860	842	828	807	Nothing active to do, just keep an eye on numbers which should rise	
END-9 Non Diabetic + GLP-1 medication	83	157	164	247	13	119	314	1097	1007	918	766	As above	
REN-08 Non preferred NSAIDs ON REPEAT(excl Ibuprofen, Naproxen)	21	31	20	7	19	46	59	203	216	211	201	Keep eye on, and no new additions	
END-3a Review Metformin as NO B12 test ever	7	50	33	24	20	16	212	362	377	397	425	Sites to review / test	
GAS-03 45yrs + NSAID on repeat + no PPI or H2	0	3	3	1	4	2	2	15	18	15	10	Review indication, stop NSAID or add protection	



MONTHLY MEDICINES MANAGEMENT QUALITY / SAFETY AUDIT

WORK TO DO

Work To Do this month (Red)	BRAN	COMB	DHG	HAV	HOW	OAK	DERB	Nov-25	Oct-25	Sep-25	Aug-25	SITES TO DO (GP / PHARMACIST / NURSE)	CENTRAL TO DO
WH-8a Topiramate on repeat and no Pregnancy Prevention Program code on record	0	1	1	0	0	0	5	7	10	9	17	Sites to do - code Pregnancy Prevention Program	
REN-03 Review ACE or ARB or Diuretic as no UE done in last 12 months (15/12)	59	91	26	23	43	15	79	336	344	344	344	Review / do bloods	
RESP-2a ?Review Inhalers as SABA with no ICS in asthma 12+ yrs	0	3	0	0	0	0	0	3	51	187	323		
RESP-3 Asthma - Review as 2 or more oral prednisolone in last 12m (+ no COPD)	45	57	73	35	62	26	125	423	418	422	415		
RESP-4b Asthma- Review as 3>= SABA inhalers in last 12m (+ no COPD)	34	232	143	163	132	85	299	1088	1091	1109	1125		